Gundersen Health System
La Crosse, Wisconsin 54601
7 studies enrolling now · 35 studies all time
What they study most
Adult Solid Tumor, Amblyopia, Arthroplasties, Knee Replacement, Asthma, Breast Carcinoma, COVID 19 Associated Coagulopathy, COVID-19, Cancer, Center Involved Diabetic Macular Edema, Cholangiocarcinoma, Coronary Artery Disease, Covid19
Studies at this site
- A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) — Recruiting now
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) — Recruiting now
- Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body — Recruiting now
- An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA) — Recruiting now
- Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age — Recruiting now
- GEMINI-NSCLC: NSCLC Biomarker Study — Recruiting now
- Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy — Running, not enrolling
- A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa — Running, not enrolling
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
- A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment — Stopped early
- Trial of Overminus Spectacle Therapy for Intermittent Exotropia — Completed
- A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma — Completed
- Registry of Asthma Patients Initiating DUPIXENT® — Completed
- Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU) — Stopped early
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE — Stopped early
- Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial) — Running, not enrolling
- The PEERLESS Study — Completed
- Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer — Completed
- Hybrid Coronary Revascularization Trial — Completed
- Patient Outcomes With Robotic-Assisted Total Knee Arthroplasty — Enrolling by invitation
- Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors — Stopped early
- Base-in Prism Spectacles for Intermittent Exotropia — Completed
- Immune Modulators for Treating COVID-19 — Completed
- Chronic Hypertension and Pregnancy (CHAP) Project — Completed
- Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia — Completed
- Covid-19 Associated Coagulopathy — Completed
- COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 — Stopped early
- Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel — Stopped early
- A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction — Completed
- Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung — Stopped early
- Integration of Exercise Into Cancer Care: A Shared Care Model — Status unconfirmed
- Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms — Status unconfirmed
- Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma — Completed
- Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI — Completed
- Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma — Stopped early